Health
Biocon Wins FDA Approval for Pebrilzo, Expanding Options for HER2-Positive Breast Cancer in U.S.
FDA’s green light for Pebrilzo, a biosimilar to Perjeta, marks a milestone in Biocon’s U.S. oncology portfolio and may widen patient access to innovative breast cancer…